Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance

• Type of Material: Article
• Authors: Michael M. Boyiadzis, University of Pittsburgh; Madhav Dhodapkar, Emory University; Renier J. Brentjens, Memorial Sloan Kettering Cancer Center; James N. Kochenderfer, National Cancer Institute; Sattva S. Neelapu, University of Texas MD Anderson Cancer Center; Marcela V. Maus, Harvard Medical School; David L. Porter, University of Pennsylvania; David G. Maloney, Fred Hutchinson Cancer Research Center; Stephan A. Grupp, University of Pennsylvania; Crystal L. Mackall, Stanford University; Carl H. June, University of Pennsylvania; Michael R. Bishop, University of Chicago
• Language: English
• Date: 2018-12-04
• Publisher: BMC (part of Springer Nature)
• Publication Version: Final Published Version
• Copyright Statement: © 2018 The Author(s).
• License: Creative Commons Attribution 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1186/s40425-018-0460-5
• Title of Journal or Parent Work: Journal for ImmunoTherapy of Cancer
• ISSN: 2051-1426
• Volume: 6
• Issue: 1
• Start Page: 137
• End Page: 137
• Grant/Funding Information: Not applicable.
• Keywords: INTERLEUKIN-12; Axicabtagene ciloleucel; Leukemia; Tisagenlecleucel; REMISSIONS; MANAGEMENT; B-CELL; IMMUNOTHERAPY; Chimeric antigen receptor; CELL MATURATION ANTIGEN; LEUKEMIA; CYTOKINE RELEASE; Science & Technology; Lymphoma; Life Sciences & Biomedicine; TUMOR-INFILTRATING LYMPHOCYTES; Immunology; Oncology; LYMPHOMA
• Research Categories: Health Sciences, Oncology; Health Sciences, Immunology; Biology, Cell

Abstract

Chimeric Antigen Receptor (CAR) T cell therapies - adoptive T cell therapies that have been genetically engineered for a new antigen-specificity - have displayed significant success in treating patients with hematologic malignancies, leading to three recent US Food and Drug Administration approvals. Based on the promise generated from these successes, the field is rapidly evolving to include new disease indications and CAR designs, while simultaneously reviewing and optimizing toxicity and management protocols. As such, this review provides expert perspective on the significance and clinical considerations of CAR T cell therapies in order to provide timely information to clinicians about this revolutionary new therapeutic class.